VVM
SKYE icon

Versant Venture Management’s Skye Bioscience SKYE Stock Holding History

Versant Venture Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Hold
250,963
– – 0.86% 7
2026
Q1 		$1.23M Hold
250,963
– – 0.87% 7
2025
Q4 		$1.51M Hold
250,963
– – 1% 6
2025
Q3 		$7.89M Hold
250,963
– – 3.71% 5
2025
Q2 		$8.39M Hold
250,963
– – 10.22% 4
2025
Q1 		$3.19M Hold
250,963
– – 5.3% 4
2024
Q4 		$5.68M Hold
250,963
– – 6.55% 4
2024
Q3 		$7.85M Hold
250,963
– – 12.35% 4
2024
Q2 		$16.1M Buy
+250,963
New +$23.8M 20.81% 3

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Versant Venture Management's SKYE Position: Q2 2026 in Review

Versant Venture Management held its Skye Bioscience (SKYE) position steady in Q2 2026 at 250,963 shares worth $1.39M. The position accounts for 0.86% of the portfolio, ranked #7.

Versant Venture Management first reported a position in SKYE in Q2 2024 and has held it in 9 quarters since. The position peaked at $16.1M in Q2 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Versant Venture Management held 250,963 shares of Skye Bioscience worth $1.39M as of Q2 2026.
  • Versant Venture Management left its Skye Bioscience share count unchanged in Q2 2026.
  • Skye Bioscience made up 0.86% of Versant Venture Management's portfolio in Q2 2026, its #7 holding.
  • Versant Venture Management first reported a position in Skye Bioscience in Q2 2024 and has held it in 9 quarters since.
  • Versant Venture Management's Skye Bioscience position peaked at $16.1M in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Versant Venture Management's 13F filing for Q2 2026, filed 12 Aug 2026.